Company news
NextTrip, Inc. news in 2020
NextTrip, Inc.'s news releases, calls and decks from 2020, newest first.
Neurotrope and Metuchen Pharmaceuticals Announce Completion of Merger Forming Petros Pharmaceuticals
December 1, 2020
Neurotrope, Inc. Approves Spin-Off of Neurotrope Bioscience, Inc. and Sets Record and Distribution Dates
November 19, 2020
Neurotrope Announces First Patient Dosed in Long-Term Clinical Trial of Bryostatin in Alzheimer's Disease
October 5, 2020
Neurotrope Shareholders to Own 49 Percent of Petros Under Revised Merger Agreement with Metuchen
September 29, 2020
Neurotrope Bioscience Announces Agreement with Worldwide Clinical Trials, to Conduct Ongoing Phase 2 Study of Bryostatin-1, Partially Funded by NIH, for Alzheimer's Disease
July 29, 2020
Neurotrope Announces Strategic Partnership with BryoLogyx for Supply of Synthetic Bryostatin-1 and Continuation of the National Cancer Institute (NCI) Trial for Childhood Leukemia
June 9, 2020
Neurotrope Launches New Long-Term Clinical Trial of Bryostatin with the National Institutes of Health for the Treatment of Patients with Alzheimer's Disease
May 27, 2020
Neurotrope Announces Investor Update Conference Call
May 25, 2020
Neurotrope and Metuchen Pharmaceuticals Announce Merger Agreement to Form Petros Pharmaceuticals, a Men's Health Company
May 17, 2020
Neurotrope Provides Corporate Update After Completing Bryostatin-1 Data Analysis for Advanced Alzheimer's Disease Trial
January 21, 2020
Neurotrope, Inc. Announces $18 Million Registered Direct Offering
January 21, 2020
Decks in 2020
- Sigma Labs — Investor Presentation (September 2020)
Investor deck · 25 slides · Sep 16, 2020